TFF Pharmaceuticals to Participate in the 12th Annual Jefferies London Healthcare Conference 2021
AUSTIN, Texas, Nov. 08, 2021 - TFF Pharmaceuticals (NASDAQ: TFFP) announced that President and CEO Glenn Mattes will present a corporate overview at the 12th Annual Jefferies London Healthcare Conference from November 16-19, 2021. The presentation will be available on demand starting November 18, 2021, at 3:00 AM ET. TFF Pharmaceuticals specializes in drug products using its patented Thin Film Freezing technology, which enhances the solubility and absorption of poorly water-soluble drugs.
The replay will be accessible for 30 days post-event on the Company’s website.
- None.
- None.
AUSTIN, Texas, Nov. 08, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will present a corporate overview at the 12th Annual Jefferies London Healthcare Conference taking place November 16-19, 2021.
| Event: Format: Date: Time: Location: | Jefferies London Healthcare Conference (November 18-19) Available on Demand Presentation and 1x1 Meetings Thursday, November 18, 2021 Available on-demand starting at 3:00 AM ET webcast link | |
Replay Link:
A replay will be accessible for 30 days following the on-demand session on the Events page of the Investors section on the Company’s website at https://ir.tffpharma.com/events-and-presentations/events.
If you are interested in arranging a one-on-one meeting virtually on either November 18th or 19th, please contact your Jefferies representative. For more information about the Jefferies London Healthcare Conference, please visit the Jefferies conference website.
About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.
Company Contacts:
Glenn Mattes
President and CEO
TFF Pharmaceuticals, Inc.
gmattes@tffpharma.com
737-802-1973
Kirk Coleman
Chief Financial Officer
TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com
817-989-6358
Investor Relations Contact:
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com
Media Contact:
Gwendolyn Schanker
LifeSci Communications
(269) 921-3607
gschanker@lifescicomms.com
FAQ
When is TFF Pharmaceuticals presenting at the Jefferies London Healthcare Conference?
What technology does TFF Pharmaceuticals utilize?
How can I access TFF Pharmaceuticals' presentation after the event?
Who is presenting for TFF Pharmaceuticals at the conference?
What are TFF Pharmaceuticals' lead drug candidates?
